Related Experiment Video

Updated: Jun 6, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

A reappraisal of Gaucher disease-diagnosis and disease management algorithms

Pramod K Mistry1, Maria Domenica Cappellini, Elena Lukina

  • 1Department of Pediatrics and Medicine, Yale University, New Haven, Connecticut 06562, USA. pramod.mistry@yale.edu

American Journal of Hematology
|November 17, 2010
PubMed

Insights

Timely diagnosis of Type 1 Gaucher disease is crucial for accessing enzyme replacement therapy. Consensus algorithms were developed to improve diagnosis and management of this rare lysosomal storage disorder.

Area of Science:

  • Biochemistry
  • Genetics
  • Metabolic disorders

Background:

  • Type 1 Gaucher disease, a lysosomal storage disorder, pioneered enzyme replacement therapy (ERT) for orphan diseases.
  • Despite available treatments, diagnostic delays affect nearly 25% of patients, hindering timely ERT access.
  • Gaucher disease symptoms are nonspecific and varied, complicating differential diagnosis despite definitive enzyme testing.

Framework:

  • A consensus meeting was convened to address diagnostic and management challenges.
  • Algorithms were developed to standardize the diagnostic pathway for Gaucher disease.
  • Protocols were established for the optimal management of diverse Gaucher disease presentations.

Implementation:

  • The developed algorithms aim to streamline the diagnostic process.
  • These guidelines facilitate earlier identification of Gaucher disease.
  • The framework supports timely initiation of enzyme replacement therapy.

Implications:

  • Improved diagnostic timelines are expected to enhance patient outcomes.
  • Standardized management protocols will optimize treatment efficacy.
  • This initiative serves as a model for addressing challenges in rare disease diagnosis and treatment.

More Related Videos

Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants06:02

Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants

Published on: November 28, 2025

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...